X
Xili Technology
A research and development company whose mission is to harness advanced technologies, machine learning/AI, and the inherent biology embedded within RNA to develop novel medicines to treat human…
About Xili Technology
ReviR Therapeutics, also known as Xili Technology, is a drug discovery company that leverages ribonucleic acid (RNA) and artificial intelligence (AI) to create new medicines. The company has developed the VoyageR AI platform, which is a machine learning system used for identifying and validating RNA drug targets. This platform is also capable of designing drugs and predicting their effectiveness.
ReviR's primary focus is on developing treatments for genetic diseases that currently have few or no therapeutic options. The company utilizes its SpliceR modulation technologies to target specific RNAs associated with these diseases. In addition to its work on genetic disorders, ReviR is also exploring applications in oncology, as evidenced by its research collaboration with Asieris Pharmaceuticals.
The company's business model appears to be centered on both internal drug development and strategic partnerships with other pharmaceutical companies. By combining computational biology with high-throughput drug discovery techniques, ReviR aims to accelerate the development of next-generation therapies for patients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- South San Francisco, United States
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 71.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Core AI, Spinout, Biotech and Pharma, AI Drug Discovery, AI Applications, DT and LS, science-based
- Technology
- Artificial Intelligence, Machine Learning
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Apr 2026 | $0 | — | CureCMT | ↗ |
| GRANTOther financing | Nov 2025 | $4.6M | — | California Institute for Regenerative Medicine | ↗ |
Growth signals
Latest recorded traffic for Xili Technology is 5K monthly website visits, up 354.5% over the last three months. Xili Technology's team grew 5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Xili Technology in the South San Francisco ecosystem
The Xili Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Shunwei Capital
CDH Investments
5Y Capital
Tiantu Capital
Sky9 Capital
California Institute for Regenerative Medicine
CureCMT
Series A4 investors entered at this stage
CMT Research Foundation- LILongpan Investment
XtalPi- YCYayi Capital
Other known investors1 additional known investor
Thomas Jefferson University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xili Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xili Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










